VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

14 1月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

12 11月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

07 11月 2024 15:05:01 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

15 10月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

23 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

06 9月 2024 07:00:11 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Departure of Chief Financial Officer

30 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

28 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

08 8月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease

29 7月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

16 5月 2024 15:05:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

16 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

09 5月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

02 5月 2024 15:05:01 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

11 3月 2024 06:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

07 3月 2024 07:00:19 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

06 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

04 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

27 2月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

22 2月 2024 06:00:00 条件 Nasdaq GlobeNewswire